Sandoz receives approval in Portugal for innovative respiratory inhaler AirFluSal® Forspiro®

  • Portuguese Health Authority grants marketing authorization for AirFluSal® Forspiro®
  • Approval for 50-250 and 50-500µg dosage forms
  • AirFluSal Forspiro already launched in four European countries and South Korea

Holzkirchen, October 09, 2014 – Sandoz announces today that the Portuguese Health Authority (Infarmed) has granted marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

AirFluSal Forspiro has now been approved in a total of 10 …

/by

Sandoz commits to providing affordable, quality eye care on World Sight Day

October 9, 2014 – Approximately 285 million people worldwide live with low vision and blindness, according to the World Health Organization. Of these, 39 million people are blind and 246 million have moderate or severe visual impairment. Often a result of poor living conditions, 90% of blind people live in low-income countries.

…
/by

Sandoz commits to providing affordable, quality eye care on World Sight Day

October 9, 2014 – Approximately 285 million people worldwide live with low vision and blindness, according to the World Health Organization. Of these, 39 million people are blind and 246 million have moderate or severe visual impairment. Often a result of poor living conditions, 90% of blind people live in low-income countries.

…
/by

US celebrates 30 years of rapid generics growth

October 01, 2014 – 30 years ago, when President Ronald Reagan signed the legislation that would lay the basis for today’s US generics industry, even the law’s biggest fans never guessed quite how successful it would be.

One estimate – optimistic at the time – was that the new legislation, commonly known today as the Hatch Waxman Act, could save Americans a total of USD 1 billion.

A study published this year by the IMS Institute for …

/by

US celebrates 30 years of rapid generics growth

October 01, 2014 – 30 years ago, when President Ronald Reagan signed the legislation that would lay the basis for today’s US generics industry, even the law’s biggest fans never guessed quite how successful it would be.

One estimate – optimistic at the time – was that the new legislation, commonly known today as the Hatch Waxman Act, could save Americans a total of USD 1 billion.

A study published this year by the IMS Institute for …

/by

Sandoz contributes to fighting the number one cause of death globally

September 29, 2014 – Today is World Heart Day. Cardiovascular disease (CVD) is a global burden accounting for 17.3 million deaths a year – significantly more than all deaths related to malaria, HIV and tuberculosis. By 2030, the World Health Organization estimates more than 23 million people annually will die of CVD.

Due to the prevalence of CVD globally, affordable medicines are a top concern for governments and health authorities. Sandoz has a broad portfolio of generic cardiovascular medications which prevent cardiovascular diseases by lowering lipid levels and …

/by

Sandoz continues women leadership program to build talent pipeline

Holzkirchen, Germany, September 26, 2014 – For the fourth consecutive year, Sandoz held the global Women@Sandoz leadership program for top women associates. Eighteen women, representing all Sandoz regions and functions, participated in the three-day event, sponsored by Sandoz Global Head, Richard Francis.

 

“We are focused on achieving and maintaining a strong gender balance at all levels, in every area of our business, because we believe diversity is good for business and inclusion is good for our people,” said Lisa Richert, Sandoz Chair of the Global …

/by

Sandoz launches Kerdyn TM (tavaborole) topical solution, 5% from Anacor Pharmaceuticals, Inc.

Princeton, New Jersey, September 22, 2014 – Sandoz, through its branded dermatology business, PharmaDerm, today announced the US launch of KERYDINTM (tavaborole) topical solution, 5%, developed  by Anacor Pharmaceuticals, Inc.

In July 2014, Sandoz announced an agreement with Anacor Pharmaceuticals, Inc. to obtain exclusive rights to commercialize KERYDINTM in the US.

KERYDINTM is the first oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes, a fungal infection of the …

/by

Generic medicines saved US healthcare system nearly USD 240 billion in 2013

September 18, 2014 – The use of generic medicines saved US patients and payors a total of USD 239 billion in 2013 – an increase of 14% over 2012 and more than in any previous year.

That was the main finding of a new study by the IMS Institute for Healthcare Informatics, commissioned by the US Generic Pharmaceutical Association (GPhA).

The latest study, details of which have just been released by GPhA, showed that the use of generics in the US saved a total of …

/by

Dealing with the spread of chronic disease in Africa

September 10, 2014 – Sub-Saharan Africa is facing a healthcare tipping point. Policy and resources are mainly dedicated to fighting infectious diseases today. HIV, malaria and tuberculosis are the big targets. But over the next 15 years chronic diseases like cancer, heart disease, and kidney failure will become the major killers. By 2030 they will account for 42% of all deaths in the region, up from 25% today, says the World Health Organization.

 

Their rise may be inevitable, but their impact could be better managed. Education, policy and health investment can …

/by